What is the recommended treatment for men who experience a hot‑flash‑type burning sensation in the head?

Treatment for Hot Flash-Type Burning Sensation in the Head in Men

For men experiencing hot flash-type burning sensations in the head (vasomotor symptoms), gabapentin or venlafaxine are the recommended first-line nonhormonal treatments, with hormonal options (medroxyprogesterone acetate or cyproterone acetate) being significantly more effective but reserved for specific clinical contexts.

Treatment Algorithm

First-Line Nonhormonal Options

Gabapentin is the preferred initial choice 1:

• Start at 300 mg at bedtime, titrate up to 900 mg/day over 1-2 weeks
• Reduces hot flash severity by approximately 46% compared to 15% with placebo
• Particularly useful if symptoms disturb sleep (due to somnolence effect)
• Key advantages: No drug interactions, no sexual dysfunction, no withdrawal syndrome
• Side effects: Dizziness, drowsiness, unsteadiness (typically resolve after first week)
• Discontinuation rate: ~10% in clinical trials 2

Venlafaxine (SNRI) as alternative first-line 1:

• Start 37.5 mg daily, increase to 75 mg daily after 1 week
• Reduces hot flashes by 47-61% depending on dose 3
• Faster onset than other options
• Side effects: Dry mouth, decreased appetite, nausea, constipation, possible sexual dysfunction
• Discontinuation rate: 10-20% 2
• Must taper gradually when stopping to avoid withdrawal syndrome

Hormonal Options (Most Effective)

Medroxyprogesterone acetate is the most effective treatment 3:

• Dose: 20 mg daily
• Reduces hot flash score by 83.7% at 1 month 3
• Significantly superior to venlafaxine (p<0.0001) in head-to-head trials
• Consider as standard treatment for men with prostate cancer on androgen deprivation therapy 3

Cyproterone acetate (equally effective alternative):

• Dose: 100 mg daily
• Reduces hot flash score by 94.5% at 1 month 3
• Caution: May interfere with hormonal therapy in prostate cancer patients 3

Second-Line Options

Clonidine 2, 1:

• Dose: 0.1 mg/day (oral or transdermal)
• Mild to moderate efficacy (reduces hot flashes up to 46%)
• Side effects: Dry mouth, insomnia or drowsiness
• High discontinuation rate (40%) limits utility 2

Paroxetine (SSRI) 4:

• Start 12.5 mg/day, increase to 37.5 mg/day over 4 weeks
• Reduces hot flash frequency from 6.2 to 2.5 per day
• Well-tolerated in pilot studies in men

Clinical Decision Points

When to Choose Gabapentin:

• First-line for most men with vasomotor symptoms
• Concurrent neuropathic pain present
• Patient wants to avoid sexual dysfunction
• Sleep disturbance is prominent symptom

When to Choose Venlafaxine:

• Concurrent depression present 2
• Faster symptom relief needed
• Patient failed gabapentin trial

When to Consider Hormonal Therapy:

• Severe, refractory symptoms after nonhormonal trial
• Patient specifically requests most effective option
• Not on active androgen deprivation therapy for prostate cancer (if using cyproterone)

Nonpharmacologic Adjuncts

Consider adding 1:

• Acupuncture (shown effective in small studies)
• Cognitive behavioral therapy (reduces perceived burden)
• Exercise/physical activity
• Weight loss if overweight
• Lifestyle modifications (avoid triggers)

Avoid: Phytoestrogens, botanicals, vitamin E (limited data, potential harm in prostate cancer) 1

Common Pitfalls

1. Starting doses too high: Use lower doses than for conventional indications to minimize side effects
2. Stopping SSRIs/SNRIs abruptly: Always taper to avoid withdrawal syndrome 2
3. Expecting immediate results: Allow 4 weeks to assess efficacy 2
4. Using cyproterone in men on active ADT: May interfere with cancer treatment 3

Treatment Timeline

• Rapid onset: All pharmacologic options show effect within 1 week 2
• Assessment point: Evaluate efficacy at 4 weeks; if no response, treatment unlikely to be effective 2
• Duration of action: Gabapentin (up to 12 weeks) > Clonidine (up to 8 weeks) > SSRI/SNRI (up to 6 weeks) 2